Previous 10 | Next 10 |
- YUPELRI® (revefenacin) is realizing strong customer acceptance and market uptake, in partnership with Mylan - Phase 1 of TD-5202 single-ascending dose and multiple-ascending dose studies evaluated the safety and tolerability of TD-5202 in healthy subjects; data showed TD-5202 was...
DUBLIN , Feb. 18, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will webcast Management presentations: SVB Leer...
This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman’s regulatory 13F Form filed on 02/13/2020. Please visit our Tracking Seth Klarman’s Baupost Group Holdings ...
DUBLIN , Feb. 13, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its fourth quarter and full year 2019 financial an...
Shares of Theravance Biopharma (NASDAQ: TBPH) were sinking 10.7% lower as of 11:04 a.m. EST on Wednesday. This decline came after the drugmaker announced the pricing of a public stock offering after the market closed on Tuesday. Theravance plans to sell 5.5 million new shares at a price of $...
Zosano Pharma (NASDAQ: ZSAN ) -47% after pricing stock offering. More news on: Zosano Pharma Corporation, PolarityTE, Inc., PDS Biotechnology Corporation, Stocks on the move, , Read more ...
Theravance Biopharma (NASDAQ: TBPH ) has priced its public offering of 5.5M ordinary shares at $27.00 per share, for expected gross proceeds of ~$148.5M. More news on: Theravance Biopharma, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
DUBLIN , Feb. 11, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, announced today the ...
DUBLIN , Feb. 10, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, announced today that...
Drug developer Theravance Biopharma (NASDAQ: TBPH) is not your typical biotech company. It emerged in 2014 from a spinoff of the R&D branch of its parent company, now called Innoviva (NASDAQ: INVA) . Shareholders in Innoviva received a dividend of Theravance Biopharma stock. The R&am...
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma Inc. Website:
2024-06-15 00:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboratio...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...